Brief: Aptose Biosciences Says Exercises Early Option For Cg-806 License From Crystalgenomics
07/05/2018 12:06
May 7 (Reuters) - Crystal Genomics Inc 083790.KQ :
* APTOSE BIOSCIENCES INC - EXERCISES EARLY OPTION FOR CG-806
LICENSE FROM CRYSTALGENOMICS
* APTOSE BIOSCIENCES INC - CO OWNS GLOBAL RIGHTS TO DEVELOP
AND
COMMERCIALIZE CG-806 FOR ALL INDICATIONS OUTSIDE OF KOREA AND
CHINA - LICENSED TERRITORY
* APTOSE BIOSCIENCES- CRYSTALGENOMICS ELIGIBLE FOR
REGULATORY AND
SALES MILESTONE PAYMENTS, AS WELL AS ROYALTIES ON PRODUCT SALES
IN LICENSED TERRITORY
* APTOSE BIOSCIENCES INC - OPTION EXERCISE TRIGGERS A
PAYMENT OF
US $2.0 MILLION TO CRYSTALGENOMICS
Source text for Eikon: ID:nGNX33GWrD
Further company coverage: 083790.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CG Invites
See all newsBrief: Cg Invites Wins 5.6 Billion Won Order
Brief: Crystalgenomics Invites Divesting 4 Billion Won Worth Of Own Shares
Brief: Kumho Ht To Divest 28 Billion Won Worth Of Shares In Crystalgenomics
Brief: Aptose Biosciences, Crystalgenomics Announce Issuance Of Australian Patent
Brief: CrystalGenomics to raise 21.1 bln won via private placement